All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALKS 4230,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
Data from the ongoing ARTISTRY-1 study showed encouraging single-agent activity of ALKS 4230 in melanoma and durable responses in multiple tumor types in combination with pembrolizumab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
The cavrotolimod pharmacodynamic profile corroborated the efficacy data, as increased serum cytokines/chemokines, activated immune cells, and tumor infiltration by immune cells were observed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALKS 4230,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
Safety and anti-tumor efficacy data from the ongoing phase 1/2 ARTISTRY-1 study, evaluating ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with refractory solid tumors, will be shared in a mini oral presentation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
The KOL meeting will focus on company's preliminary Phase 1b efficacy and safety data for cavrotolimod, Exicure’s SNA-enabled TLR9 agonist for solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
The dose expansion stage is designed to assess the anti-tumor response rate of cavrotolimod plus checkpoint inhibitor treatment, the safety and tolerability of the combination, and drug pharmacodynamics and pharmacokinetics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AST-008,Pembrolizumab,Cemiplimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Poster presentation will show updated pharmacodynamic and safety data of AST-008 from Exicure’s ongoing Phase 1b/2 study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AST-008,Pembrolizumab,Cemiplimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
The poster will present updated pharmacodynamic and safety data of AST-008 alone and in combination with pembrolizumab from Exicure’s ongoing Phase 1b/2 study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALKS 4230
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2020
Details:
In preclinical model, ALKS 4230 exhibited improved anti-tumor efficacy and lower toxicity relative to recombinant human IL-2.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
